SCHEMBL2200905

SCHEMBL2200905

CCOC(=O)c1c(-c2ccncc2)n[nH]c1C1CC1

nearest known ligand 0.46

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CDK5 Q00535 1/20 0.46
CDK5R1 Q15078 1/20 0.46
MAPK11 Q15759 8/20 0.45
MAPK14 Q16539 8/20 0.45
ALDH1A1 P00352 1/20 0.45
HPGD P15428 1/20 0.45
HSD17B10 Q99714 1/20 0.45
KCNH2 Q12809 1/20 0.44
CDC7 O00311 4/20 0.42
DBF4 Q9UBU7 4/20 0.42
HPGDS O60760 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
ADORA3 P0DMS8 1/20 0.41
LMNA P02545 1/20 0.41
KMT2A Q03164 1/20 0.41
MAPK1 P28482 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
KDM4E B2RXH2 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4442104 0.87 HTT (0.53) HPGDSSMN1; SMN2ADORA3KMT2AKDM4E
SCHEMBL2197680 0.85 PDE4D (0.40) CDK5CDK5R1ALDH1A1HPGDHPGDS
SCHEMBL2200266 0.82 PDE4D (0.58) ALDH1A1HPGDHSD17B10CDC7DBF4
SCHEMBL10920620 0.80 ALDH1A1 (0.49) ALDH1A1HPGDHSD17B10CDC7DBF4
SCHEMBL10921097 0.80 ALDH1A1 (0.49) ALDH1A1HPGDHSD17B10CDC7DBF4
SCHEMBL25211948 0.80 ALDH1A1 (0.55) ALDH1A1HPGDHSD17B10CDC7DBF4
SCHEMBL2201791 0.77 PDE4D (0.63) ALDH1A1HPGDHSD17B10SMN1; SMN2ADORA3
SCHEMBL17129029 0.72 DUSP3 (0.48) ALDH1A1HPGDHSD17B10CDC7DBF4
SCHEMBL20471495 0.72 KDM4E (0.50) ALDH1A1HPGDSMN1; SMN2LMNAKMT2A
SCHEMBL6726705 0.71 CDC7 (0.49) CDK5CDK5R1ALDH1A1HPGDHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7977358-B2 Pyrazol derivatives HOFFMANN-LA ROCHE INC. (US) 2011-07-12 US disclosed
EP-2182953-A2 NEW PYRAZOL DERIVATIVES F. Hoffmann-Roche AG (CH) 2010-05-12 EP disclosed
US-20090029963-A1 PYRAZOL DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2009-01-29 US disclosed
WO-2009013211-A2 NEW PYRAZOL DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2009-01-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090029963-A1 PYRAZOL DERIVATIVES CCR1, CCR3, CCRL2 CDK5 464/4885CDK5R1 210/4885MAPK11 955/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.